Table 4.
Multivariate analysis of CSS of patients with NSCLC.
| Variables | Multivariate analysis | |
|---|---|---|
| HR (95% CI) | P | |
| Age | 1.01 (1.01–1.01) | <0.001 |
| Sex | ||
| Female | 1 (Reference) | 1 |
| Male | 1.23 (1.19–1.26) | <0.001* |
| Race | ||
| White | 1 (Reference) | 1 |
| Black | 0.99 (0.95–1.02) | 0.403 |
| Other** | 0.73 (0.70–0.77) | <0.001* |
| Histology | ||
| Adenocarcinoma | 1 (Reference) | 1 |
| Squamous carcinoma | 1.22 (1.18–1.26) | <0.001* |
| Large cell lung cancer | 1.49 (1.38–1.61) | <0.001* |
| Other lung cancer | 1.31 (1.26–1.37) | <0.001* |
| Site | ||
| Upper lobe | 1 (Reference) | 1 |
| Middle lobe | 0.96 (0.90–1.03) | 0.262 |
| Lower lobe | 1.02 (0.99–1.05) | 0.196 |
| Main bronchus | 1.19 (1.12–1.25) | <0.001* |
| Overlapping | 1.24 (1.10–1.39) | <0.001* |
| Non–specified | 1.14 (1.09–1.19) | <0.001* |
| Laterality | ||
| Right | 1 (Reference) | 1 |
| Left | 0.99 (0.96–1.01) | 0.307 |
| Bilateral | 0.92 (0.83–1.03) | 0.142 |
| TNM stage | ||
| IA | 1 (Reference) | 1 |
| IB | 2.03 (1.81–2.29) | <0.001* |
| IIA | 3.49 (3.08–3.96) | <0.001* |
| IIB | 4.14 (3.69–4.66) | <0.001* |
| IIIA | 6.12 (5.56–6.74) | <0.001* |
| IIIB | 7.80 (7.05–8.64) | <0.001* |
| IV | 14.10 (12.85–15.47) | <0.001* |
| Country % with employed | ||
| 1.29–5.8% | 1 (Reference) | 1 |
| 5.81–7.06% | 0.99 (0.95–1.02) | 0.533 |
| 7.07–8.53% | 0.94 (0.91–0.98) | 0.001* |
| 8.54–17.16% | 0.97 (0.94–1.01) | 0.136 |
| Surgery | ||
| No surgery | 1 (Reference) | 1 |
| Surgery | 0.35 (0.33–0.36) | <0.001* |
| Chemotherapy | ||
| No | 1 (Reference) | 1 |
| Yes | 0.49 (0.48–0.51) | <0.001* |
| SES stage | ||
| SES I | 1 (Reference) | 1 |
| SES II | 1.21 (1.18–1.24) | <0.001* |
CSS, cancer-specific survival; NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; SES, socioeconomic status.
*
Indicates significance of P < 0.05.
**
Indicates American Indian/AK Native, Asian/Pacific Islander and unknown.